Quarterly report · Q2
3353.TEDINET S100S0UE
Period2023-03-01 → 2023-08-31
Filed2023-10-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥17.5bn | 2023-03-01 → 2023-08-31 | Cons. | Net sales |
| Revenue | ¥33.9bn | 2022-03-01 → 2023-02-28 | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.0bn | 2022-03-01 → 2022-08-31 | Cons. | Net sales |
| Operating income | ¥603m | 2023-03-01 → 2023-08-31 | Cons. | Operating income |
| Operating income | ¥466m | 2022-03-01 → 2022-08-31 | Cons. | Operating income |
| Ordinary income | ¥697m | 2023-03-01 → 2023-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-03-01 → 2023-02-28 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥598m | 2022-03-01 → 2022-08-31 | Cons. | Ordinary income |
| Profit before tax | ¥776m | 2023-03-01 → 2023-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥624m | 2022-03-01 → 2022-08-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥444m | 2023-03-01 → 2023-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥760m | 2022-03-01 → 2023-02-28 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥374m | 2022-03-01 → 2022-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥469m | 2023-03-01 → 2023-08-31 | Cons. | Profit loss |
| Net income | ¥386m | 2022-03-01 → 2022-08-31 | Cons. | Profit loss |
| Total assets | ¥28.5bn | at 2023-08-31 | Cons. | Assets |
| Total assets | ¥27.5bn | at 2023-02-28 | Cons. | Assets |
| Total assets | ¥28.3bn | at 2022-08-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥15.4bn | at 2023-08-31 | Cons. | Liabilities |
| Total liabilities | ¥14.9bn | at 2023-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥13.1bn | at 2023-08-31 | Cons. | Net assets |
| Net assets / equity | ¥12.6bn | at 2023-02-28 | Cons. | Net assets |
| Net assets / equity | ¥12.2bn | at 2022-08-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.7bn | at 2023-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.4bn | at 2023-02-28 | Cons. | Cash and deposits |
| Cash & equivalents | ¥6.5bn | at 2023-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.3bn | at 2023-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.8bn | at 2022-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.8bn | at 2022-02-28d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥848m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2022-03-01 → 2023-02-28 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥496m | 2022-03-01 → 2022-08-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥338m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥478m | 2022-03-01 → 2023-02-28 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥291m | 2022-03-01 → 2022-08-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥217m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.4bn | 2022-03-01 → 2023-02-28 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.2bn | 2022-03-01 → 2022-08-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥118.26 | 2023-03-01 → 2023-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.84 | 2023-06-01 → 2023-08-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥202.2 | 2022-03-01 → 2023-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥99.65 | 2022-03-01 → 2022-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.26 | 2022-06-01 → 2022-08-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 43.9% | at 2023-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.8% | at 2023-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.2% | at 2022-08-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-03-01 → 2023-08-31 | −¥472m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-03-01 → 2023-08-31 | −¥472m |
| Reconciling Itemsreconciling | segment profit | 2023-03-01 → 2023-08-31 | −¥387m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥780m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥111m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥2.1bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥1.6bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥470m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥34m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥93m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥91m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥2m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥66m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-03-01 → 2023-08-31 | ¥17.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-03-01 → 2023-08-31 | ¥17.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥472m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-03-01 → 2023-08-31 | ¥990m |
| Reconciling Itemsreconciling | revenue | 2022-03-01 → 2022-08-31 | −¥497m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-03-01 → 2022-08-31 | −¥497m |
| Reconciling Itemsreconciling | segment profit | 2022-03-01 → 2022-08-31 | −¥385m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥11.6bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥11.6bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥736m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥35m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥1.9bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥1.4bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥495m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥20m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2022-03-01 → 2022-08-31 | ¥95m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2022-03-01 → 2022-08-31 | ¥94m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥876,000 |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2022-03-01 → 2022-08-31 | ¥61m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-03-01 → 2022-08-31 | ¥17.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-03-01 → 2022-08-31 | ¥17.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-03-01 → 2022-08-31 | ¥497m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-03-01 → 2022-08-31 | ¥851m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 499
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03443-000DispensingPharmacyReportableSegmentsMember | 11580107000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03443-000HealthCareReportableSegmentsMember | 3902225000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 1898007000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03443-000RealEstateReportableSegmentsMember | 95199000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 17475539000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -496549000 | JPY |
| Net sales | Prior1YTDDuration | 16978990000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03443-000DispensingPharmacyReportableSegmentsMember | 736051000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03443-000HealthCareReportableSegmentsMember | 34684000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 19623000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03443-000RealEstateReportableSegmentsMember | 60541000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 850901000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -385256000 | JPY |
| Operating income | Prior1YTDDuration | 465645000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03443-000DispensingPharmacyReportableSegmentsMember | 11861141000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03443-000HealthCareReportableSegmentsMember | 3899552000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 1598645000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03443-000RealEstateReportableSegmentsMember | 91141000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 17450480000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 17450480000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03443-000DispensingPharmacyReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03443-000HealthCareReportableSegmentsMember | 300000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 469627000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03443-000RealEstateReportableSegmentsMember | 2327000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 472254000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -472254000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E03443-000DispensingPharmacyReportableSegmentsMember | 11861141000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E03443-000HealthCareReportableSegmentsMember | 3899852000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 2068272000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E03443-000RealEstateReportableSegmentsMember | 93468000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 17922735000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -472254000 | JPY |
| Net sales | CurrentYTDDuration | 17450480000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E03443-000DispensingPharmacyReportableSegmentsMember | 779749000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E03443-000HealthCareReportableSegmentsMember | 110740000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 33863000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E03443-000RealEstateReportableSegmentsMember | 66084000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 990438000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -387384000 | JPY |
| Operating income | CurrentYTDDuration | 603054000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)東海財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-10-13 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第39期第２四半期（自 2023年６月１日 至 2023年８月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社メディカル一光グループ | |
| Company name in english cover page | FilingDateInstant | Medical Ikkou Group Co.,Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 南野 利久 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |